SBIR-STTR Award

The primary objective of this effort is to improve existing methodologies for assay of hemoglobin Ale in human blood by utilizing monoclonal antibody technology in the development of an immunospecific assay. The clinical usefulness of the assay as an objective measure of long-term carbohydrate control of diabetic patients, in monitoring and encouragement of patient compliance, in reversal of certain pathological sequelae of diabetes, in lowered perinatal mortality and morbidity to pregnant diabetics, in minimization of hypoglycemic reactions, and as an adjunctive test of high specificity in the diagnosis of diabetes mellitus, has been favorably discussed in recent literature.The Phase I effort consists of the preparation of highly purified hemoglobin A1C as an immunogen and the production and initial characterization of monoclonal antibodies from hyperimmunized mice. Complete characterization of the monoclonal antibodies and incorporation of them into one of two alternative approaches to develop a highly sensitive, highly specific immunoassay for hemoglobin Ale is planned under Phase II. The uniqueness of the product derives from the anticipated improvement in sensitivity and specificity over existing methodologies, and the high likelihood of commercial success is assured by a large existing market which will grow with increasing awareness and a better test.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

The primary objective of this effort is to improve existing methodologies for assay of hemoglobin A c in human blood by utilizing monoclonagl antibody technology in the development of an immunospecific assay. In recent literature, the clinical usefulness of the assay as an objective measure of long-temm carbohydrate control of diabetic patients has been favorably discussed. The assay can also be used in monitoring and encouragement of patient compliance, in reversal of certain pathological sequelae of diabetes, in lowered perinatal mortality and morbidity to pregnant diabetics, in minimization of hypoglycemic reactions, and as an adjunctive test of high specificity in the diagnosis of diabetes mellitus.Phase II efforts consist of completing the characterization of the monoclonal antibodies specific for hemoglobin A1c and hemoglobin A0 produced under Phase I funding; production of additional monoclonal antibodies, seeking those with optimal affinities; incorporation of the antibodies in one of three alternative approaches; and evaluation of the utility and performance of the optimized assay in different clinical conditions. The uniqueness of the proposed highly sensitive and specific enzyme immunoassay derives from the anticipated improvements over existing methodologies, and the high likelihood of commercial success is assured by a large existing market, which will grow with increasing awareness and a better test.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)